Christopher D. Alafi, Director, 10% Owner at Intra-Cellular Therapies, Inc. (ITCI), bought 517,048 shares at $15.50 ($8.0M) on 2017-10-02, disclosed to the SEC on 2017-10-03.
Seasonal purchase ($8.0M) by Director, 10% Owner — this insider has traded ITCI in October in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 918 | $0 | 0.0% |
| 2 | $15.50 | 258,065 | $4.0M | 50.0% |
| 3 | $15.50 | 258,065 | $4.0M | 50.0% |
| Total | $15.47 avg | 517,048 | $8.0M | 100% |
| Filing → |
| ITCI | BUY | 2020-09-14 | $1.5M | — | Filing → |
| ITCI | BUY | 2020-09-11 | $590K | — | Filing → |
| ITCI | BUY | 2019-09-11 | $9.8M | — | Filing → |